“Efficacy, Durability, And Retreatment Outcomes Of Risankizumab In Moderate To Severe Plaque Psoriasis: Results From The Phase 3 Immhance Trial”. 2016. Journal of Carcinogenesis 15 (1). https://doi.org/10.64149/.